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Unless diagnosed early, many adult cancers remain incurable diseases. This is despite an intense
global research effort to develop effective anticancer therapies, calling into question the use of
rational drug design strategies in targeting complex disease states such as cancer. A fundamental
challenge facing researchers and clinicians is that cancers are inherently robust biological systems,
able to survive, adapt and proliferate despite the perturbations resulting from anticancer drugs.
It is essential that the mechanisms underlying tumor robustness be formally studied and
characterized, as without a thorough understanding of the principles of tumor robustness,
strategies to overcome therapy resistance are unlikely to be found. Degeneracy describes the
ability of structurally distinct system components (e.g. proteins, pathways, cells, organisms)
to be conditionally interchangeable in their contribution to system traits and it has been broadly
implicated in the robustness and evolvability of complex biological systems. Here we focus on
one of the most important mechanisms underpinning tumor robustness and degeneracy, the
cellular heterogeneity that is the hallmark of most solid tumors. Based on a combination of
computational, experimental and clinical studies we argue that stochastic noise is an underlying
cause of tumor heterogeneity and particularly degeneracy. Drawing from a number of recent data
sets, we propose an integrative model for the evolution of therapy resistance, and discuss recent
computational studies that propose new therapeutic strategies aimed at defeating the adaptable
cancer phenotype.
Introduction
Although modern therapies have increased patient lifespan,
the majority of adult cancers remain terminal diseases.1 This is
because anticancer drugs generally lose efficacy due to the
emergence of therapy resistance within tumors, which remains
a significant obstacle to long-term patient survival. Some
cancers, such as acute myeloid leukemia and ovarian and
breast cancers, show an initial response to chemotherapeutics
but invariably relapse, with the recurrent cancer often resistant
to any further therapeutic intervention.2 Other cancers such
as melanoma and pancreatic and colon cancers contain
fewer proliferating cells during therapy, but the tumor mass
nonetheless remains stable within the patient throughout
treatment.2 Tumors utilize many mechanisms to avoid and/or
overcome chemotherapeutics. The diversity of drug evasion
mechanisms that are observed in tumors, combined with the
challenge of effective in vivo drug delivery, renders the
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Insight, innovation, integration
Despite an intense global research effort, most adult
cancers remain incurable. The challenge facing researchers
is that cancer is a complex disease, displaying many trait
properties that drive tumor progression. One such trait
property is therapy resistance, widely regarded as the greatest
obstacle preventing long-term patient survival. Here we
integrate findings from mathematical models, experimental
systems and clinical studies to provide an updated schema
for the evolution of cancer therapy resistance. In this new
paradigm, selectively filtered cellular and sub-cellular hetero-
geneity provides cancer with the crucial property of
degeneracy, rendering tumors both robust and evolvable.
We then explore the latest generation of conceptual and
computational models that, by directly attacking tumor
evolvability, have proposed new therapeutic paradigms that
may help reduce or overcome therapy resistance in tumors.
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identification and targeting of therapy-resistance mechanisms
difficult.
Trait robustness is a ubiquitous and fundamental property
at all organizational scales in biology and is prevalent for
instance in gene expression, protein folding, metabolic flux,
physiological homeostasis, development, and organismal
fitness.3,4 Here we define robustness as ‘a property that allows
a system to maintain its function despite internal and external
perturbations’.5 Robustness requires the maintenance of
system function as opposed to simply maintaining a stable
state,4 and biological systems often achieve this robustness
through adaptation, a principle dramatically illustrated in the
anhydrobiosis of tardigrade, which can suspend their meta-
bolism under conditions of extreme dehydration, surviving for
years in a dormant state.6 Adaptive change is not a unique
property of extremophiles as cancers, an inherently robust
disease system, are able to adapt to and accommodate many
different physiological insults, such as low oxygen and
metabolic stress.7 In this review we argue that selection
occurring over cellular trait heterogeneity is one of the
fundamental causes of cancer robustness. In cancer, cell trait
heterogeneity originates from under-regulated stochastic
processes at the genetic, epigenetic and protein expression
levels. Studies of tumor heterogeneity have revealed extensive
cellular trait variation within tumors with respect to size,
morphology, antigen expression and membrane composition.8
Individual tumor cells also display diverse functional behaviors
in terms of proliferation rate, cell–cell interactions, metastatic
potential and sensitivity to therapy.8 Sequencing studies have
demonstrated surprising levels of genetic diversity between
individual patient tumors of the same type.9 Heritable intra-
tumoral heterogeneity increases the probability of tumors
harboring a therapy-resistant phenotype and has been hypo-
thesized to endow tumors with the necessary adaptability to
survive and recur after treatment.7,10,11 More generally, we
propose that tumor heterogeneity provides the phenotypic
diversity necessary for the rapid evolution that occurs in many
cancers.
Evolvability is defined as ‘the capacity to generate heritable,
selectable phenotypic variation’.12 Since the seminal paper
from Nowell in 1976 describing cancer as an evolutionary
system,13 many studies support the idea that tumors are indeed
evolving systems.14 In this paradigm individual cancer cells
become the reproductive units within the population, and
those cells that have acquired a survival advantage through
random genetic or heritable epigenetic change are selected
through multiple rounds of clonal expansion, during which
they acquire further alterations that combine to produce a
malignant phenotype.15 For evolution to occur there must be
some form of selection pressure combined with sufficient
heritable variation within the population. Many such selection
pressures exist for tumor cells in vivo, such as limited nutrients,
oxidative stress, and competition for space, as well as extrinsic
factors such as immuno-surveillance and anticancer
therapeutics.14
In melanoma,16 colon cancer17 and esophageal cancer,18 an
increasing number of genetic mutations characterize different
phases of neoplastic progression, suggesting a model of
sequential mutation acquisition during tumor evolution.
This has been best characterized in adenocarcinomas of the
large intestine, in which the number of oncogeneic mutations
correlates with tumor grade and stage.19 Notably, when
isolating different stages of neoplasia in the same tumor
specimen, Vogelstein and colleagues demonstrated that
although identical ras mutations were present in both regions,
the more aggressive carcinomatous regions contained at least
one mutation that was absent in the less aggressive adenomatous
region.17 This sequential model of tumor progression supports
the idea that successive mutation enhances the fitness of
the tumor cells, followed by positive selection and clonal
expansion. However as with any evolutionary process, the
sequential progression observed in these studies is likely
providing a ‘selection-biased’ perspective on an underlying
stochastic process involving genetic drift, hitchhiking and
other dynamic population properties.8,20
More direct evidence for tumor evolution was provided
recently in breast cancer. By comparing all somatic coding
mutations in a metastatic breast cancer relative to the original
primary tumor resected nine years previously, Shah et al.
revealed that only five of 32 coding mutations found in the
metastases were present in the original tumor, demonstrating
that evolution had occurred during disease progression.21 A
recent genetic analysis of breast tumors has so far provided the
clearest picture of tumor evolution in vivo. By studying the
cellular composition of breast tumors, Wigler and colleagues
identified multiple clonal subpopulations.22 The observation
that all subpopulations within a single tumor shared many
of the same chromosome breakpoints provides additional
supporting evidence for an evolutionary model of tumor
growth, with new clones evolving out of pre-existing tumor
cells.22
Further support for the idea of evolution driving tumor
development comes from studying the emergence of tumor
therapy resistance. In lung cancer, mutant clones containing
point mutations within the epithelial growth factor (EGF)
receptor drive tumor recurrence that is resistant to further
EGF receptor inhibition.23 Likewise, resistance to Glivec in
chronic myeloid leukemia is often due to mutant clones with
point mutations within the BCR-ABL tyrosine kinase.24,25 In
the case of Glivec resistance in chronic myeloid leukemia,
there is evidence that resistant mutants are present in patient
tumors before drug treatment,26 suggesting that cancer
therapies select for pre-existent resistant mutants within
tumors. This is reminiscent of natural selection acting on
standing genetic variation which is believed to occur in many
biological contexts27 such as in bacterial populations, where
pre-existing resistant mutants drive the evolution of bacterial
phage resistance.28
Given these findings, we propose that a better understanding
of the principles of tumor evolvability will allow for the design
of new therapeutic paradigms that minimize or inhibit tumor
evolution, and thus prevent the emergence of therapy
resistance. As heritable phenotypic variation is a prerequisite
of tumor evolution, we first focus our attention on four
mechanisms thought to be responsible for generating tumor
heterogeneity in patients: genetic instability, epigenetic
instability, stochastic protein dynamics and tumor micro-
environments. Next we provide a brief analysis of the crucial
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relationship between robustness and evolvability. We then
present an integrative model of tumor evolution in which we
propose how heterogeneity at different biological scales can
facilitate evolution and the generation of complex tumor
properties. Finally, we explore how a systems biology
approach may be used to help overcome robust, evolvable
tumors in patients.
Sources of heterogeneity
1 Genomic instability
Heterogeneity within tumor genomes. The Cancer Genome
Atlas has published DNA sequences from numerous cancers,
providing many fundamental insights into tumor biology. The
identification of mutant genes driving transformation was the
primary goal of these sequencing studies.29 The systematic
characterization of cancer genomes revealed the unexpected
finding that most cancer types display significant intertumor
mutational heterogeneity.15 Most solid tumors contain on
average 50 non-silent mutations in the coding regions of
different genes, with only a small fraction of these genes being
mutated across tumors.15 For example, when Greenman et al.
sequenced 518 protein kinases in 210 tumors of different
origins and identified 1007 likely driver mutations,30 very
few commonly mutated genes were identified. This finding
also holds true within individual tumor types, as sequencing of
brain, pancreatic and colon cancers has revealed that only a
few common mutations exist for each tumor type.29,31–34
Studies in breast and colon cancer have confirmed the diverse
mutational heterogeneity within these tumors underpins their
immunological heterogeneity.35–37
Sequencing technologies are now sufficiently advanced to
allow researchers to begin assessing intra-tumor genomic
heterogeneity. Recent sequencing of a primary breast tumor
using next-generation sequencing confirmed that intermediate
grade breast tumors do indeed contain clonal subpopulations.21
By developing a new technology termed sector-ploidy-profiling
(SPP) Navin et al.22 revealed that primary breast carcinomas
consist of either a single major clonal population, or several
primary clonal subpopulations.22 Given that this technology
currently lacks the sensitivity to detect uncommon clones
within populations,22 this first pass almost certainly under-
estimates the true level of genetic heterogeneity present in solid
tumors. Nevertheless these initial studies provide the impor-
tant proof-of-principle that intra-tumor genetic heterogeneity
exists, and begin to shed light on the evolutionary dynamics
occurring within tumors.21,22
The mutator phenotype model. What is driving genomic
heterogeneity within tumors? The mutator model of tumor
initiation posits that mutations that increase genomic instability
(the so called mutator phenotype) drive tumorigenesis by
allowing tumor cells to rapidly acquire the portfolio of
mutations required for cellular transformation through an
increase in random mutation events. This idea, pioneered
and championed by Loeb and colleagues, was initially based
on the analysis of DNA polymerases and DNA repair
enzymes,38 but has subsequently been expanded to include
other sources of genomic instability common to tumors.39–41
For example, chromosomal instability generates many
chromosomal defects in tumors, including aneuploidy, trans-
locations, inversions, interstitial deletions, amplifications and
loss-of-heterozygosity.42 Multiple mechanisms drive chromo-
some instability including activation of key oncogenes known
to drive cellular transformation (reviewed in ref. 42 and 43),
providing tumors with ample capacity to generate genomic
instability.
A firm theoretical foundation supporting the mutator model
has been provided by recent modeling studies. The first study,
undertaken by Beckman and Loeb, assumed that all potential
mechanisms of tumorigenesis are in operation. The major
insight of this work was the novel idea that mechanisms that
produce malignant lineages most efficiently should be considered
the most likely to generate clinical cancers.44 In this model,
efficiency is defined as the number of malignant lineages
generated in a given time. This schema allowed the first direct
comparison of the relative efficiencies of mutator and non-
mutator pathways in cancer lineage production,44 and demon-
strated that mutator mutations increase the efficiency of
tumorigenesis under many realistic simulation conditions.44
Most compellingly, the mutator phenotype became increasingly
important as the number of mutations required for cellular
transformation rose.44 Thus, for tumors requiring only two
mutations, the mutator phenotype offers no advantage.44
However, when the number of mutations required for transfor-
mation exceeds six, then the mutator phenotype imparts a
significant advantage in the efficiency of tumorgenesis.44
As stated by Jarle Breivik ‘Each random mutation may be
regarded as a bet, and the odds are always unfavorable, simply
because there are more ways to damage a genome than
improve it. As for roulette, you may get a lucky strike, but
the more bets you make, the more certain it is that you will
lose’.45 Clonal extinction due to reduced fitness is known as
negative clonal selection and is one of the most serious
criticisms leveled against the mutator model.45 To directly
address whether negative clonal selection negates the mutator
hypothesis, Beckman recently developed an updated model
that incorporated the mutator’s reduced fitness within its
underlying assumptions.46 This model revealed that even with
negative clonal selection, mutator cells still provide the
most efficient route to tumorigenesis.46 The model made an
important new prediction: that there exists an optimal muta-
tion rate for tumors, above which the deleterious effects of
reduced fitness do lead to negative clonal selection and tumor
collapse.46 Support for this idea has recently been generated
using bacterial competition models, where Loeb and colleagues
experimentally confirmed that mutator strains of E. coli
displaying a high mutation rate invariably suffer negative
clonal selection and die out, whereas those mutator strains
that fall within a narrow optimal range of mutation rates
consistently prevail and survive in evolutionary competition
assays.47 Importantly, these results suggest that mutator cells
are not necessarily doomed to extinction due to reduced
fitness.47 Beckman’s updated model also confirmed two predic-
tions of the earlier model: that mutator mutations are most
likely to occur early in tumorigenesis, and that the mutator
phenotype becomes increasingly important as more oncogenic
mutations are required for transformation.44,46 In an
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independent study, Zhou et al. explored evolutionary
dynamics in silico using a numerical model based on Highly
Optimized Tolerance (HOT),48 a mathematical paradigm used
to understand how selectively acquired robustness can lead to
the evolution of complexity.49 In this model, mutators played
a primary role in adaptation, whereas low-mutators preserved
well-adapted phenotypes.48 Taken together, these three
models support the hypothesis that mutator phenotypes both
increase the efficiency of tumorigenesis (and thus increase the
probability of tumor initiation) and drive tumor adaptation
throughout disease progression.
The correlation between tumor incidence and advanced age
has been used to estimate that the minimum number of genetic
mutations that drive oncogenesis is five to six.50–52 Pediatric
tumors such as retinoblastoma require significantly fewer
mutations for transformation,53–55 whereas late-onset adult
tumors may require as many as 10–12 events.56 Experimental
models initially suggested that 3–4 mutations were sufficient to
generate transformed cells.57 However recent experimental
data indicates that more mutations are in fact required.
Mahale et al. explored the efficiency of transformation using
a combination of four oncogenes in a human fibroblast model
of transformation.58 Using this established experimental
system they made the striking observation that tumorigenicity
significantly increased after serially passaging tumor cells
either in vitro or in vivo. The observed increase in tumorigenicity
correlated with the selection of dominant clones, suggesting
that malignant transformation is a stochastic process initiated
by the four defined oncogenes, but that full transforma-
tion involves clonal selection of tumors harboring further
transforming mutations.58 Nicholson and Duesberg then
extended these analyses to reveal fundamental differences in
the karyotypes and phenotypes of clones derived from a single
parent cell with four oncogenes, providing direct evidence that
evolution had indeed occurred during expansion both in vitro
and in vivo.59 These authors went on to demonstrate that
individual clones evolve further during serial passaging in
culture, generating either enhanced tumorigenicity or drug
resistance in vitro.59 These findings are consistent with recent
reports showing a correlation between genomic instability and
drug resistance,60,61 supporting the idea that the rate of tumor
evolution, including the acquisition of therapy resistance, is
significantly enhanced by genomic instability. Taking a
complementary approach and working in parallel, the
systematic and comprehensive analysis of Ye et al. showed
that tumorigenicity is positively associated with genomic
diversity in five independent models of tumor progression.62
These combined data sets provide experimental evidence for a
direct causal relationship between genomic instability and
cancer evolution.
Direct confirmation of this relationship came recently using
a mouse model of genomic instability.63 Sotillo et al. induced
lung tumor formation in mice by doxycyline-mediated expression
of oncogeneic Ras either alone or in combination with Mad2,
a knownmediator of chromosomal instability.63 The expression
of oncogenic Ras alone generated lung tumors, whereas Mad2
expression alone did not. However the addition of chromo-
some instability through Mad2 co-expression markedly
enhanced Ras tumorigenicity, as revealed by a more rapid
disease onset and mortality, a more aggressive tumor pheno-
type, and a two-fold increase in the size of the Ras + Mad2
tumors compared to tumors expressing Ras alone.63 The
increased aggressiveness of Ras + Mad2 tumors correlated
with increased aneuploidy (a marker of chromosomal instability)
and a rise in the diversity of Ras + Mad2 tumor sub-types
compared to the Ras-only control.63 When the oncogenic
protein expression was ablated by doxycycline withdrawal,
both the Ras and the Ras + Mad2 tumors collapsed,
consistent with the idea of oncogenic Ras expression
driving tumor growth. Ras-only tumors never recurred after
doxycycline withdrawal. In striking contrast, approximately
half of the Ras + Mad2 tumors returned, with recurrent
tumors displaying both increased aneuploidy and new signal
transduction pathway activation.63 The most plausible inter-
pretation of these results is that the increased genomic
instability of the the Ras +Mad2 tumor allowed the evolution
of Ras-independent tumor cells, which then drove tumor
recurrence despite the loss of oncogenic Ras expression.
2 Epigenetic instability
It has been cogently argued that as a single genome is capable
of generating the diversity of cell phenotypes present in
metazoan organisms, the same mechanisms that underpin
normal cell diversity may also drive tumor heterogeneity and
contribute to tumor evolution.64 Cell diversity in somatic
organisms is regulated through epigenetic mechanisms. By
epigenetics we mean ‘the study of mitotically and/or meiotically
heritable changes in gene function that cannot be explained by
changes in DNA sequence’.65 This fulfils the biologists defini-
tion of ‘a stably heritable phenotype resulting from changes in
a chromosome without alterations in the DNA sequence’66
while accommodating the existence of pseudo-stable states
driven by network dynamics and long-lived stochastic
fluctuations.
Deregulated chromatin structure as a source of epigenetic
heterogeneity. The structure of chromatin determines how
genetic information is organized within the cell.67 Chromatin
consists of repeating units of nucleosomes, which in turn are
made up ofB146 bp of DNA wrapped around an octomer of
four core histone proteins (H3, H4, H2A and H2B).68 The
organization of the genome into discrete structures provides
mechanisms for regulating whether genes are active or silent.
Epigenetic mechanisms used to modify chromatin structure,
and hence control gene expression, can be divided into three
categories: DNA methylation, covalent histone modification,
and non-covalent mechanisms such as incorporation of novel
histone variants (reviewed in ref. 69). These modifications
work together to alter the structural dynamics of chromatin
to create an epigenetic profile that sits atop the genetic base,
shaping the output of the mammalian genome to regulate
developmental stages and define discrete cell types.69
This epigenomic profile is extensively distorted in cancers.69
Cancers display global changes in DNA methylation, covalent
modifications of histones, extensive non-covalent changes, and
altered expression profiles of chromatin-modifying enzymes.67
These ‘epimutations’ can silence tumor-suppressing genes and
activate oncogenes, and are likely to be functionally equivalent
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to genomic cancer mutations.70 Indeed, we now know that
hundreds of genes are either silenced or activated in cancers
due to epigenetic changes, and the list continues to grow.67,71
Although epigenetic alterations are reversible, they are mitotically
heritable, and therefore available to natural selection and able to
actively participate in tumor evolution.70
Intriguingly, multiple epigenetic aberrations have been
directly linked to genomic instability (reviewed in ref. 70).
DNA hypomethylation at repeat sequences increases genomic
instability by promoting chromosomal rearrangements.72
Hypomethylation of transposable elements can lead to their
activation and translocation, increasing genomic instability.73
Genomic instability can also be caused by epigenetic inactiva-
tion of genes encoding DNA repair proteins.74,75 Indeed, the
silencing of the DNA repair protein MGMT and global DNA
demethylation are thought to be early initiating events in
tumor formation.76–78 Thus epigenetic modifications are well
placed to contribute directly to genomic instability and tumor
heterogeneity, thereby enabling tumor evolution.
Deregulated regulatory RNA as a source of epigenetic hetero-
geneity. It is now clear that regulatory RNAs are directly
linked to tumorigenesis and progression by acting as either
oncogenes or tumor supressors.79 The best characterized
regulatory RNAs contributing to cancers are microRNAs
(miRNAs), small RNAs that are generally 22 residues long
and form the sequence-specific part of the RNA-induced
silencing complex (RISC) that binds to mRNAs and inhibits
their translation and stability.79 Shortly after their discovery in
mammals, a series of studies revealed that a significant number
of miRNAs display altered expression in various tumors.80–85
It has now been experimentally confirmed that some miRNAs
induce or accelerate tumorigenesis, acting as oncogenes.86,87
Other miRNAs function as tumor suppressors, displaying
anti-proliferative or pro-apoptotic functions in experimental
models.88,89
One of the primary functions of miRNAs in normal develop-
ment is the stabilization of cellular phenotypes.79 Regulatory
loops play a central role in maintaining robust phenotypic
reproducibility of developmental programs.90 This type of
system control comprises a collection of feedback loops that
monitor and quantitatively regulate the output of signaling
networks.91 Negative feedback loops embedded within signaling
networks are prevalent and are known to stabilize pathway
dynamics.91 Experimental evidence suggests that an important
role of miRNAs is to impose stabilizing negative feedback
loops during development.92,93 In line with this function,
miRNA expression is reduced in late-stage tumors and correlates
with tumor aggressiveness, which is thought to be due to an
increase in tumor heterogeneity resulting from destabilized
pathway dynamics.79
Deregulated network dynamics as a source of epigenetic
heterogeneity. Normal lineage commitment and differentiation
is regulated through complex regulatory networks. Networks
containing large numbers of mutually regulating com-
ponents can generate multiple stable equilibrium states, called
attractors.94,95 These stable states have been proposed to
correspond to different differentiated cell types within an
organism by driving cell-type-specific gene expression
patterns.94 A pure attractor is a stable state driven by the
balance between regulatory loops within a genetic network
and is not the result of covalent modifications. In reality,
attractors are likely to result from a combination of regulatory
loops within kinase cascades, non-coding RNA networks,
genetic networks and chromatin remodeling. An epigenetic
landscape contains all the possible stable attractor states and
the unstable transition states.96 Normal cellular differentiation
is governed by growth factors, cellular contextual cues, cell
cycle regulators and complex regulatory loops, which define
the attractors in normal tissue differentiation. In cancer,
although many of these regulatory signals are deregulated,
there remains an epigenetic landscape littered with patho-
logical attractors that represent cancer cell states. Tumor cells
therefore have access to a variety of connected attractor states,
allowing tumors to display some of the characteristics of a
complex developmental phenotype.96
The cancer stem-cell model in light of the epigenetic land-
scape. An epigenetic landscape populated with diverse attrac-
tor states provides an integrative view of cancer that
accommodates many disparate observations, making it a
powerful paradigm to understand tumor biology. For example,
some of the controversies about the cancer stem cell model of
cancer (see ref. 97) may be reconciled using the epigenetic
landscape paradigm. The cancer stem cell hypothesis states
that a subset of tumor cells with stem cell-like properties
drive tumor initiation, progression, and recurrence.97 These
‘cancer stem cells’ have the purported ability to self-renew
indefinitely, generate rapidly cycling progenitor cells which
then differentiate into all cell types within the tumor, thereby
generating the tumor bulk and intercellular trait heterogeneity.
In effect, tumors represent a pathological simulacrum of
normal tissue growth, with chaotic tumor differentiation a
parody of the controlled differentiation program that occurs in
healthy tissue. Tumor progression arises from the metastatic
spread of cancer stem cells and, importantly, disease
recurrence is then thought to be due to the accelerated
repopulation of cancer stem cells that are inherently therapy
resistant.98 The generality of this hypothesis has, however,
recently been questioned.99,100 A possible explanation for the
disparate results in the literature regarding the existence or
otherwise of cancer stem cells could rest with what could be
called the stability of the epigenetic landscape of individual
tumors. Cancers with a stable epigenetic landscape have
correspondingly stable attractors, locking cancer cells into
defined states. Here cancer cells occupying attractors with
‘stem cell’ properties are predicted to play a central role in
driving the tumor biology, including tumor initiation and
therapy resistance, even though they are genetically identical
to their non-stem cell counterparts. From an epigenetic land-
scape perspective, the cancer stem cells would sit atop a
hierarchy of connected attractors that radiate outward to
stable attractors representing distinct cell fates. This statement
follows from the assumption that the initial epigenetic land-
scape has been carefully shaped over evolutionary time to
establish distinct cell-fate pathways, and that the tumor has
maintained some of this developmental architecture. However,
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very aggressive tumors with high levels of genetic and
epigenetic instability would be expected to display a progressive
deregulation of the epigenetic landscape, resulting in attractors
that become increasingly less stable and that no longer connect
with the same clear hierarchical architecture (see Fig. 1). As a
result of deregulation, the cancer stem cell attractor should be
less critical in driving disease, because cancer cells are able to
move more freely between different attractor states, including
transitions to what might have once been a cancer stem cell
phenotype.
Recent experimental evidence from malignant melanoma
provides support for this model.101 Roesch et al. recently
identified a slow-cycling subpopulation of cells within melanoma
tumors that functions as the tumor-maintaining cell population.101
These slow-cycling tumor-maintaining cells express JARID1B,
a histone 3 K4 (H3K4) demethylase that in healthy organs is
highly expressed in regenerative tissues.102–104 In melanoma,
JARID1B is associated with negative regulation of the cell
cycle.105,106 Knockdown of JARID1B initially stimulated
tumor growth, however growth could not be maintained in
the absence of JARID1B,101 revealing the JARID1B cell
subpopulation as crucial in maintaining continual tumor
growth. Intriguingly, JARID1B expression appears to be
dynamic, with JARID1B-negative cells able to spontaneously
generate JARID1B-positive cells and vice versa.101 Together
these results and other findings reviewed in ref. 107 argue
against a hierarchical cancer stem cell model, instead suggesting
that melanoma tumor-initiating cells are generated spontaneously
or induced by environmental cues within the melanoma tumor
bulk, consistent with the idea of pseudo-stable attractor states
driving tumor growth in aggressive cancers.
Unstable epigenetic states add another layer of complexity
to tumor biology, the phenomenon of transient therapy resistance.
The existence of a transiently resistant drug state within
tumors was first proposed based on the observation that some
drug-resistant tumors become responsive after a break
from treatment.108–110 A recent study has provided experi-
mental confirmation that transient drug resistance does occur
in lines derived from multiple cancers, driven by epigenetic
modification.111 Transient treatment of tumor cells with various
chemotherapeutics has identified a small fraction of quiescent
cells that areB500 fold less sensitive to anticancer drugs than
their parental cells.111 In clonally derived populations, drug
tolerance emerges de novo and is reversible, although it can
become stabilized over time.111 Transient drug resistance is
driven by activation of the insulin growth factor 1 (IGF-1)
receptor and an altered chromatin state requiring histone
demethylase RBP2.111 Importantly, the transiently drug-
resistant subpopulation can be ablated using inhibitors of
IGF-1 or chromatin-modeling agents, suggesting an avenue
of therapeutic redress for future studies.111 In combination
with clinical studies108–110 the study of Sharma et al. provides
support for the existence of a transient drug-resistant attractor
states that reflect states within a deregulated epigenetic land-
scape. Moreover, with each cell displaying slightly unique
epigenetic landscape properties and different positioning
within the landscape, tumors could be endowed with an
enormous repertoire of transient cell responses that enhances
the tumor’s overall robustness in the face of therapy. This idea
is well established in bacterial populations where phenotypic
outliers contribute to population fitness, one relevant example
being the so called ‘persisters’ in bacterial populations that
express an increased resistance to penicillin that can then be
inherited.112–115
3 Stochastic protein dynamics
Recent work has focused attention on the role of stochastic
protein expression fluctuations in generating trait hetero-
geneity within clonal populations.116 When analyzed by
flow-cytometry, protein abundance in clonal mammalian cell
populations can vary by as much as three orders of magnitude
due to stochastic fluctuation.64,116 This variation imparts
several important characteristics on the clonal population.
First, the outliers of the population can display very different
biological properties,116 showing that purely stochastic effects
can generate functionally diverse subpopulations within a
clonal group of cells.116 In mammalian cells, such stochastic
fluctuations in protein expression can be reasonably long lived,
lasting up to 11 days in culture,116 meaning that they can
impart phenotypic variety over clinically relevant timeframes.
Recent work provides support that these types of stochastic
fluctuations do indeed afford tumors protection from anti-
cancer drugs, with Cohen and colleagues discovering significant
cell-to-cell variability in the temporal behavior of drug-
induced protein expression, which correlated with the ability
of cells to resist drug-induced apoptosis.117 This finding,
together with the study of Sharma et al. described in the
previous section, provide the first evidence that transient
non-genetic phenotypic states contribute to therapy resistance
in tumors and may explain historical studies showing tumors
that repopulate after a drug treatment can sometimes remain
sensitive to that drug.118 Even though transient states are, by
definition, relatively short lived and therefore invisible to
natural selection, transient resistant states can potentially
contribute to the evolution of therapy resistance. While several
possible pathways to inheritance exist, one plausible mechanism
would involve clonal expansions originating from mutations
that alter regulation of the epigenetic landscape and stabilize
the drug resistant phenotype. This model fits with the recent
Fig. 1 (Left panel) An illustration of hierarchy within an epigenetic
landscape for a single transition pathway from stem cell (C) to final
cell type (A). (Right panel) Deregulation and modification of the
epigenetic landscape as a consequence of genetic instability and the
mutator phenotype. The illustration is modified from ref. 177 and was
originally created to illustrate the recently discovered existence of
hierarchy within the conformational landscape of large proteins.
D
ow
nl
oa
de
d 
on
 3
1 
Ju
ly
 2
01
2
Pu
bl
ish
ed
 o
n 
14
 O
ct
ob
er
 2
01
0 
on
 h
ttp
://
pu
bs
.rs
c.
or
g 
| do
i:1
0.1
039
/C0
IB0
004
6A
View Online
This journal is c The Royal Society of Chemistry 2011 Integr. Biol., 2011, 3, 17–30 23
observation of transient drug resistant states becoming
stabilized over time,111 and may help explain the biology of
chronic myeloid leukemia (CML), where a rare subpopulation
of quiescent CML cells resists conventional therapy and is
thought to drive disease relapse.119
4 The tumor micro-environment
Genetic, epigenetic and stochastic protein dynamics sources of
heterogeneity do not act in isolation, as important cross-scale
interactions also take place within tumors. Tumor cells
continually interact with the surrounding tumor micro-
environment, a relationship that has crucial roles in tumor
initiation and progression. One relevant example is regions of
low oxygen (hypoxic regions) commonly found within solid
tumors that are the result of an imbalance between supply and
consumption of oxygen.120 Many cancers including squameous
cell carcinoma of the uterine, head and neck cancers, breast
cancers and brain tumors have regions of low oxygen in
contrast to normal adjacent tissue.121,122 Patients with hypoxic
tumors have significantly lower overall survival,121 with
hypoxia an independent prognostic factor for poor clinical
outcome in many tumors,118 indicating that hypoxic regions
play an active role in tumor malignancy.
Hypoxic regions within tumors contribute to tumor hetero-
geneity in at least three ways. First, tumor cells in hypoxic
environments display reduced expression of DNA repair genes
and corresponding increased levels of genomic instability.120,123
Thus hypoxia can contribute directly to the mutator pheno-
type and might enhance tumor evolution. Consistent with this
idea, hypoxic tumor cells display increased resistance to
radiation and drugs124,125 as well as an increased incidence
of both apoptosis-resistant126 and invasive clones,127 supporting
the hypothesis that hypoxic environments drive tumor cell
evolution towards more aggressive phenotypes. Second,
hypoxic environments can directly regulate the epigenetic state
of tumor cells. Cells in hypoxic regions are dependent on
anaerobic glycolytic metabolism,128 which in turn acidifies the
hypoxic region through the generation of lactic acid.128 The
combination of low oxygen and low pH triggers tumor cell
cycle arrest and quiescence,120,128 increasing phenotypic
heterogeneity and rendering tumor cells insensitive to many
anticancer therapies as described above. A third confounding
factor is that the low vascularization responsible for hypoxic
regions reduces the concentrations of drugs within hypoxic
regions,129 a condition known to favor selection of drug-
resistant clones.130
The tumor microenvironment is composed of many non-
transformed cell types such as endothelial cells, fibroblasts,
and immune cells, all of which interact with tumor cells and
modulate the tumor microenvironment.131 There is a large
body of research demonstrating that tumorigenesis is strongly
influenced by the non-malignant cells within the tumor micro-
environment (reviewed in ref. 132). It is likely that tumor cells
co-evolve with their micro-environments, and during the
course of disease progression changes in micro-environment
create local differences in selection pressure, thereby driving
some of the heritable differences that are observed across
cancer cells within a single tumor. From this perspective, at
least some of the phenotypic, genetic and epigenetic diversity
observed at the cell population level is likely to be a natural
consequence of tumor-microenvironment interactions. These
ideas are discussed in detail in recent reviews.14,131,133
Heterogeneity and degeneracy as an enabler of
tumor robustness and evolvability
Above we explored how tumor heterogeneity provides the
phenotypic variation required for natural selection to act
upon, thereby increasing tumor evolvability. Next we briefly
examine how tumor heterogeneity may enhance tumor robustness
and evolvability by endowing tumors with the system property
of degeneracy. Degeneracy is the ability of structurally
dissimilar system components to perform the same function
or generate the same output.134 Like robustness, degeneracy is
also a ubiquitous property of biological systems.134 It is
important to note that degeneracy is distinct from the simpler
design principle of redundancy. In redundant systems, multiple
identical components are present within the system, one
important example being the multiplicity of pacemaker cells
that robustly regulate heartbeat. Redundancy is common both
in engineering and biology, where it provides robustness in
response to very specific perturbations, e.g. compensating for
the loss or failure of an identical component. In contrast
to redundant components, degenerate components perform
similar functions within certain contexts but distinct and
separate functions in others. For degeneracy to arise, system
components must display functional plasticity, i.e. context-
sensitivity in the different functional responses generated by
each component. Recent analyses indicate that the conditionally
overlapping functionality of degenerate components plays a
fundamental role in reconciling requirements of robustness
and evolvability in nature.135
For instance, recent in silico simulation experiments
have revealed that networks composed of redundant multi-
functional proteins (i.e. proteins having either identical or
completely unique functions) are robust but do not provide
a system with mutational access to very many distinct heritable
phenotypes.135 Allowing multi-functional proteins to partially
overlap in functionality (i.e. protein degeneracy) resulted in
networks that were both exceptionally robust and exceptionally
evolvable.135 This relationship between degeneracy, robust-
ness and evolvability appears to arise at many different scales
in biological systems but has yet to be fully understood.134 On
the one hand, having diversity amongst functionally similar
components will enhance robustness in a manner that is
straightforward to understand. If components are somewhat
different, they also have somewhat different weaknesses: a
perturbation or attack on the system is less likely to present
a risk to all components at once.136 Edelman and Gally have
documented numerous biological examples of this relationship
between degeneracy and robustness.134
One clinically important example of this relationship
between degeneracy and tumor cell robustness comes from
receptor tyrosine kinase (RTK) coactivation in tumor cells.137
The epidermal growth factor receptor (EGFR) is amplified,
mutated or rearranged in over 40% of Glioblastoma multi-
forme (GBM) tumors,138,139 the most common and aggressive
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primary brain cancer in adults. Nevertheless most GBM
patients whose tumors are driven by oncogenic EGFR fail
to respond to specific EGFR inhibitors, despite the fact that
oncogenic activation of the EGFR is a crucial transforming
event for these tumors.140 It was discovered that multiple
RTKs are co-activated in GBM tumors, and as many RTKs
share common downstream components, co-activation of
multiple RTKs allows GBM tumors to maintain robust
signaling simply by switching RTK usage in the presence of
specific inhibitors.141,142 Combinations of RTK inhibitors
were required to overcome degenerate RTK usage in GBM
tumor cells.141,142 The RTK coactivation strategy has
subsequently been observed in other tumor types, suggesting
that degenerate RTK usage may represent a general
pathway by which tumor cells evade targeted therapies
(reviewed in ref. 137).
The example above describes how robustness can be
achieved through direct functional compensation. While this
mechanism is intuitively obvious, degenerate components
might also collectively contribute to the stability of many
traits simultaneously, distributing robustness throughout a
system.143 As reviewed in ref. 136 and 143 there is some
evidence to suggest that degenerate components can allow
systems to establish networked compensatory pathways whose
inherent versatility in resource usage enables buffering against
a much greater variety of perturbations than can be accounted
for by direct functional compensation alone.135
In some respects, the theoretical relationship between
degeneracy and evolvability is also straightforward to under-
stand. Because degenerate components are only conditionally
similar, circumstances can arise where the components display
unique functions and these can contribute to measurable trait
differences.134 At the molecular level, this is observed in the
conditional silencing of single nucleotide polymorphisms
within protein coding genes. A conditional similarity affords
synonymous codons mutational access to amino acids that are
the same for some mutations but different for others. For
example, in the synonymous arginine codons CGG and CGT,
the former can access amino acids {Leu; Pro; Gly; Gln; Trp}
through single point mutation, while the latter can reach
{Leu; Pro; Gly; His; Ser; Cys}. On the one hand, this provides
synonymous codons with higher mutational robustness. On
the other hand, by drifting over silent mutations, this also
increases mutational access to amino acid residues. It has
recently been shown that this conditional silencing can be
exploited to enhance the evolvability of bacterial cell lines.144
Degeneracy might also facilitate evolvability in more complex
and less direct ways. For instance, it has been proposed that
the compensatory actions of degenerate proteins can lead to
cryptic differences between cell states that only become
realized as measurable trait differences at some later time,
e.g. when thresholds for trait stability are crossed.143 In either
scenario, it is the conditional similarity amongst degenerate
components that is believed to afford robustness while
providing the requisite variety of distinct phenotypes that is
necessary for evolvability.143 While these theoretical develop-
ments and supporting studies appear promising, the complexity
of biological systems has so far precluded a thorough experi-
mental assessment of this proposed role of degeneracy in
facilitating robustness and evolvability. However the functional
divergence of redundant genes in many organisms, combined
with large-scale gene deletion studies in yeast, worms and plants
provides compelling support for the role of degeneracy as an
enabler of robustness and evolution (reviewed in ref. 145).
Degeneracy within a cancer cell appears to play an impor-
tant role in tumor robustness as seen by the ability of tumor
cells to co-activate multiple RTKs.141,142 However, individual
cancerous cells within a heterogeneous tumor are also likely to
express both distinct and overlapping functional outputs
thereby establishing degeneracy at a higher organizational
level within the tumor. This idea is supported by the ability
of tumor cells to stochastically switch from one cell state to
another, such as alternating between tumor-initiating versus
proliferative cell states,101 or adopting transient drug-resistant
states.111,117 These studies provide the first evidence that
individual tumor cells can functionally replace other cell types
within the tumor. Cells that switch to a new cell state will not
necessarily be identical to those cells being replaced, and
therefore could harbor heritable trait differences with survival
characteristics, such as therapy resistance. In this way degeneracy
within the cell population could directly facilitate tumor
evolvability, and may provide a general explanation for the
evolution of therapy resistance in aggressive cancers.
The relationship between robustness and evolvability
in tumors
A cohesive paradigm characterizing the intimate relationships
between robustness and evolvability, which is fundamental
to our understanding of biology, has until recently eluded
theoreticians.12,143,146–148 While evolvability is repeatedly seen
to support the robustness of higher level traits, it is not clear
that robustness always supports evolvability. For instance,
it is apparent that evolvability increases a cell population’s
robustness by enabling the population to adapt.5,12 On the
other hand, trait robustness within the cell seems to oppose
evolvability, as cells that are robust to mutational change
would be expected to have difficulty discovering distinct
heritable phenotype that allow for adaptation to environ-
mental change.149
A series of computational studies have resolved this tension
by showing how robustness and evolvability arise at different
timescales and furthermore showing phenotypic robustness to
be a precondition to evolution.147,150–152 Robust phenotypes
allow a population to accumulate neutral mutations, increasing
genotypic diversity.147 Because many of these neutral genotypes
harbor distinct phenotypically consequential sensitivities to
further genetic modification, mutational robustness enhances
access to phenotypic diversity over time, facilitating evolution.147
The idea that robustness facilitates evolution has strong
experimental support. Bloom et al. found that only robust
(thermostable) protein variations could tolerate the destabilizing
mutations needed to confer novel activities, whereas non-
robust (thermosensitive) proteins could not evolve new
activities.153 Measuring evolution of thermotolerance in an
RNA virus, McBride and co-workers found that populations
derived from robust clones evolved greater resistance to heat
shock relative to populations founded by non-robust
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clones.154 These studies provide direct empirical evidence that
robustness can facilitate evolvability. Chaperone proteins such
as Hsp90 function to buffer the expression of genetic and
epigenetic variation, increasing an organism’s robustness to
mutation.155 Chaperones have been shown to function as an
enabler of evolution in both eukaryotes156 and prokaryotes.157
Tumors make good use of the buffering ability of chaperones;
Hsp90 buffers tumor cells against mutations that impinge
signaling,158,159 or are lethal.160,161 These combined studies
support the hypothesis that molecular and cellular robustness
facilitates tumor evolvability.
An integrative model of tumor robustness and
evolvability
1 Increasing evolutionary potential through tumor degeneracy
The studies presented in this review emphasize several research
trends that we propose could form the basis of a new
integrated model of tumor robustness and evolvability. First,
a tumor precursor cell that acquires a mutator phenotype
within a narrow optimal range has a reasonable probability of
acquiring sufficient transforming mutations to become a
mature, malignant cancer cell before accumulating deleterious
mutations and suffering negative clonal selection. The mutator
phenotype is also predicted to generate a destabilized
epigenome, allowing cells to transiently adopt multiple
discrete cell fates and further increase genomic instability
(positive feedback). Stochastic protein dynamics within
individual cells can in some cases help to further enhance the
diversification of cell states within the tumor, amplifying the
phenotypic heterogeneity generated through (epi)genomic
instability. The net effect of this three-tiered destabilization
is the generation of a high degree of cellular trait heterogeneity
within the tumor, which affords the cancer a greater repertoire
of responses to the perturbations it encounters during growth,
thus rendering it a more adaptable and robust system. For
instance, with individual tumor cells able to transiently
adopt a variety of cell fates, individual cells of one type can
functionally replace other cell types through environment-
induced trait plasticity. On the other hand, these compensa-
tory cell transitions do not result in identical cell states
(the cells are degenerate) and cells of a similar type will display
unique strengths and weaknesses that play out in a competitive
environment to the overall benefit of tumor robustness. With
many traits having a heritable basis, transient resistance can
transform into persistent tumor properties under sustained
selective pressure, i.e. genetic assimilation.162,163 In short, we
propose that enhanced tumor robustness and evolvability is
conferred through the development of degenerate selective
repertoires that arise naturally in cell populations presented
with genetic instability, epigenetic instability, and stochastic
protein dynamics. These proposed relationships between tumor
robustness, degeneracy, and evolvability are summarized
in Fig. 2.
While the studies reviewed in this article support the model
described above, there are aspects of the proposed model that
could be modified or elaborated upon and still be supported by
the accumulated evidence within these studies. For instance,
under the mutation-selection balance that constrains the like-
lihood of initial disease onset within the mutator hypothesis, a
mutator phenotype would not be highly maladaptive if
preceded by (selectively passive) mutations that elevate the
mutational robustness (i.e. attenuated phenotypic effects from
mutations) through so called capacitance or genetic buffering
of a pre-cancerous cell. Examples of common tumor muta-
tions that can increase genetic capacitance include p53 loss-of-
function (=loss of apoptotic response to DNA damage),
constitutive PI3-kinase signaling (pushing cells into a proliferative
anti-apoptotic state) and increased chaperone expression
(direct increase in genetic buffering). Stochastic fluctuations
in protein expression may also serve as a genetic buffering
system by compensating for loss-of-function mutations or
suppressing deleterious protein expression. With elevated
levels of genetic buffering, a clonal population could sub-
sequently acquire a mutator phenotype under nearly neutral
conditions, thereby enhancing the overall likelihood of the
mutator phenotype pathway. Even in the absence of elevated
genetic buffering, mutational robustness is exceptionally high
in eukaryotic genomes compared to the more compact
genomes of viruses and bacteria,164 and this genetic neutrality
should increase the plausibility of a mutator phenotype
pathway beyond the conditions suggested from the simulation
studies reviewed earlier.
2 Increasing evolutionary potential through cryptic heritable
variation in tumors
Counter-intuitively, high levels of mutational robustness163
within cancer cells may also have a direct positive impact on
a tumor’s ability to evolve therapy resistance. While heritable
phenotypic diversity is a precondition for evolutionary
adaptation, the competitive environment within a tumor will
suppress trait differences that are deleterious to cell survival
and fecundity and will thereby impose some constraints on the
type and amount of phenotypic heterogeneity that can arise;
both within a cell population microenvironment and across
the entire tumor. However, due to the cell’s inherent genetic
and epigenetic capacitance, mutations can readily accumulate
in a cell population that appear phenotypically cryptic
(or selectively hidden) under stabilizing selection but that
become expressed or released under perturbed (e.g. stressful)
environmental conditions. This conditional exposure of
trait variation is often discussed as a phenomena known as
cryptic genetic variation (cgv) or ‘‘hidden reaction norms’’
(for reviews see ref. 165 and 166). cgv describes heritable
phenotypic variation that is hidden under ‘‘normal conditions’’
but that is released in the presence of novel alleles or novel
environments.
Given the high mutational robustness within the human
genome, a mutator phenotype should facilitate an accelerated
accumulation of high levels of this cryptic genetic variation
that can be subsequently (partially) released in ways that
depend on the stressful environments encountered. This
scenario, inherent mutational robustness combined with
elevated (epi)genetic instability, is particularly promising
because it would provide the necessary fuel for tumor adapta-
tion under new stressful environments while bypassing the
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negative clonal selection that limits phenotypic variability
under stable conditions.
While cryptic genetic variation has been observed in a
variety of species and cell populations,165,166 the origins of
cgv are not fully understood, making it unclear when or how
genetic buffering mechanisms will permit cgv to arise. Very
recent simulation studies have found that each of the hallmark
features of cgv are readily observed in biological simulations
when mutational robustness is achieved through biomolecular
degeneracy.167 Because degeneracy is ubiquitous at protein,
complex assembly, and molecular pathway levels within the
cell, it would thus seem plausible that cgv can accumulate in
tumor cell populations. Moreover, under the mutator pheno-
type scenario, cgv should accumulate rapidly and strongly
influence the evolvability of cancer.
Using a systems biology approach to attack robust
and evolvable tumors
Keeping firmly in mind Horrobin’s fears that biomedical
research is becoming a ‘glass bead game’ with little contact
with reality,168 we now focus on the design of new therapeutic
strategies that combat tumor evolvability in an effort to
mitigate therapy resistance. Our overarching hypothesis is that
an understanding of the principles of tumor evolvability
will allow the design of general therapeutic paradigms that
minimize tumor evolution, in the hope of preventing or
delaying the emergence of therapy resistance. There has
been a significant body of research devoted to developing
mathematical models of the evolution of therapy resistance,
with the aim of developing general dosing strategies to inhibit
tumor evolution.169–173 Below we focus on three recently
published modeling approaches that illustrate how combining
simulations, theory, and empirical evidence could help in the
development of therapeutic strategies that can overcome the
evolution of therapy resistance.
As even a small number of resistant cells at the start of the
therapy can prevent a cure, Foo and Michor recently modeled
the worst-case scenario of the inevitable emergence of therapy
resistance due to a single (epi)genetic mechanism.174 Impor-
tantly, they have taken into account the effects of drug toxicity
and side effects174 in an approach designed to give the best
outcome for the patient by comparing continuous or pulsed
therapy regimes, determined by the maximal time before
tumor recurrence occurs.174 The assumptions used in this
analysis are consistent with the high probability of resistance
experienced in clinical trials. Foo and Michor found that
strategies involving drugs delivered in high dose pulses,
effectively slowing the net growth of resistant cells, provided
the best outcome for patients in silico with respect to delay of
tumor recurrence and drug toxicity.174 This high-dose-pulse
approach may be useful in identifying optimum therapy
schedules to avoid or delay resistance driven by a single
(epi)genetic event.174
In their recent manuscript, Silva and Gatenby have taken an
ecological approach in their war on cancer.175 Inspired by
successful biological control of pest species in ecosystems, they
seek to stabilize rather than cure patient tumors, thereby
Fig. 2 Three tiers of noise-genetic instability, epigenetic instability, stochastic protein dynamics, and the feedback between these tiers-provides a
strong source of divergence in the internal and external properties of cancer cells, i.e. the mutator phenotype. Cellular robustness achieved (in part)
through degeneracy allows for high amounts of heritable heterogeneity to accumulate in a cell population. While the mutator phenotype
introduces new heritable variants at a rapid rate, canalization will hide, and selection will filter, the phenotypic diversity that is actually observed in
a microenvironment-dependent fashion. Other factors such as genetic drift and tumor expansion can also influence the speed and extent that
heritable variation accumulates. When presented with novel environmental conditions such as the administration of a new drug therapy,
directional selection will then act on any of the standing genetic variation that is expressed as selectively relevant phenotypic differences. Some of
this phenotypic variation is pre-existing and some is conditionally exposed by the new therapy. The overall extent of heritable phenotypic variation
will influence the propensity to evolve a persistent therapy resistance and thus impact the robustness of the cancer.
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avoiding the introduction of strong selective forces that drive
the evolution of therapy resistance. Fundamental to their
model is the assumption, based on experimental data sets
and historic modeling results, that resistant cells are present
within the tumor at low numbers due to their reduced fitness
compared to sensitive tumor cells.175 The aim of their
therapeutic approach is to maintain a sufficient number of
the rapidly proliferating, sensitive cells throughout therapy to
compete with and suppress the emergence of the slower-
cycling resistant clones. An additional insight in the work of
Silva and Gatenby is the incorporation of the role of the tumor
microenvironment, specifically hypoxic regions, in modulating
drug accessibility to resistant tumor cells within the hypoxic
zone. To overcome the hypoxic barrier to therapy, Silva
and Gatenby took advantage of tumor cell dependence on
glycolytic metabolism by using the glucose competitor
2-deoxy-glucose to target resistant cells within the hypoxic
tumor core. This was combined with a standard chemotherapy
that targeted sensitive, proliferating cells on the tumor edge.
How well do patients do on this ‘adaptive therapy’ strategy
compared to traditional therapy regimes? In silico simulations
suggest that the patients would survive significantly longer
when the two therapies were administered as separate doses,
with the best results obtained when the resistant cells were
first targeted with 2-deoxy-glucose then sensitive cells attacked
with the chemotherapy.175 This approach managed to
eradicate the resistant subpopulation, heralding the possibility
of tumor elimination and patient remission.175 A potential
criticism of this work is the untested biological assumptions
that underpin the model. However, previous work by the same
group has shown adaptive therapy maintains a significantly
lower tumor burden than conventional therapy approaches in
an established animal tumor model,176 providing promising
experimental support for the efficacy of this approach.
Our model of tumor evolution introduced in the previous
section highlights important relationships arising in natural
evolution that could inform the development of new therapeutic
paradigms. For instance, the cgv pathway outlines a process
by which tumor adaptation arises due to drug therapy
induced traits that are otherwise selectively hidden within
the extant genetic and epigenetic diversity. Even with the high
(epi)genetic instability that is associated with a mutator
phenotype, any accumulation of cgv will take time and this
imposes important restrictions on the adaptive response
capabilities of a tumor. For instance, if drug therapies cause
the release of cgv under directional selection, this would also
act to momentarily reduce cgv and transiently lower the
tumor’s evolvability to additional stresses. Assuming the cgv
pathway significantly contributes to tumor evolution, we
propose that a drug regimen that cycles through drug therapy
sequences with a timing that maximizes the rate of cgv release
could drive tumors to a more fragile state and help lead to
their ultimate demise.
While the perspectives on tumor evolution proposed in our
model are all reliant upon the onset of degenerate heritable
phenotypes through genetic and epigenetic destabilization,
there are differences in the timing and conditions for trait
heterogeneity expression that could have significant implica-
tions to therapeutic strategies. As robustness arises from the
presence of multiple partially overlapping pathways for
the establishment and maintenance of traits, we predict that
this would confer a predisposition towards single target
resistance because suppressed pathways are compensated for
by degenerate pathways. For polygenic traits that have a
large and distributed mutational target, directed selection
(under new stress conditions) is more likely to evolve
cells with enhanced degenerate pathways,134,135 which
according to one study could potentially lead to multiplicative
effects on cellular robustness over time.143 While degeneracy
at the cell population level (cgv) can be theoretically
eliminated using the sequential drug strategy suggested
above, this would be less effective against late stage cancers
if a mutually supporting network of new degenerate path-
ways were to become fixated within the cancer genome. In
these circumstances of newly adapted cellular robustness,
multi-target therapies acting on complementary pathways
might provide the only promising avenue for complete
eradication.
Conclusion
Cancer is a complex disease, displaying emergent properties
that are driven by an evolvable (epi)genome that is fueled by
stochastic noise and the contextual, dynamic interactions that
occur within tumor environments. One such emergent property
is therapy resistance, widely regarded as the greatest obstacle
to long-term patient survival. Recent studies using mathematics,
cell biology, animal models and clinical data have started to
unravel mechanisms underpinning evolvability in tumors.
These ideas have in turn inspired the development of
mathematical models that, by integrating an understanding
of the mechanisms of tumor robustness, therapy resistance and
tumor evolvability, are providing a new tool in the identifica-
tion of novel dosing strategies that may help to delay or
prevent the emergence of therapy resistance in human cancer
patients.
By viewing cancer as a robust, evolvable system, a number
of researchers are now coming to the conclusion that single
therapeutic targets might be fundamentally unsuitable as a
general treatment strategy because the inherent heritable
variation in cancer makes it a moving and elusive target. As
emphasized in ref. 107, targeted therapy approaches are likely
to fail if the molecular targets are present in only a subset of
proliferating cancer cells. Instead, we propose that directly
attacking the origins of cancer evolvability using therapeutic
strategies that reduce heritable variation could provide a
rational alternative approach.
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